Becton Dickinson and Co banner

Becton Dickinson and Co
NYSE:BDX

Watchlist Manager
Becton Dickinson and Co Logo
Becton Dickinson and Co
NYSE:BDX
Watchlist
Price: 154.85 USD -0.51% Market Closed
Market Cap: $44.1B

EV/OCF

17.7
Current
20%
Cheaper
vs 3-y average of 22.2

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
17.7
=
Enterprise Value
$68.3B
/
Operating Cash Flow
$3.4B

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
17.7
=
Enterprise Value
$68.3B
/
Operating Cash Flow
$3.4B

Valuation Scenarios

Becton Dickinson and Co is trading below its 3-year average

If EV/OCF returns to its 3-Year Average (22.2), the stock would be worth $194.06 (25% upside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-6%
Maximum Upside
+25%
Average Upside
12%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 17.7 $154.85
0%
3-Year Average 22.2 $194.06
+25%
5-Year Average 22 $192.13
+24%
Industry Average 18.7 $163
+5%
Country Average 16.7 $145.58
-6%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
US
Becton Dickinson and Co
NYSE:BDX
44.1B USD 17.7 25.1
US
Intuitive Surgical Inc
NASDAQ:ISRG
170B USD 54.1 59.5
US
Abbott Laboratories
NYSE:ABT
160.6B USD 16.9 25.6
US
Stryker Corp
NYSE:SYK
126.1B USD 27.2 38.8
IE
Medtronic PLC
NYSE:MDT
107.5B USD 17.4 23.3
US
Boston Scientific Corp
NYSE:BSX
97.4B USD 23.6 33.6
DE
Siemens Healthineers AG
XETRA:SHL
40.6B EUR 15.8 19.2
US
Edwards Lifesciences Corp
NYSE:EW
46.3B USD 26.5 43.1
US
IDEXX Laboratories Inc
NASDAQ:IDXX
44.7B USD 38.1 42.2
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
31.9B USD 18.6 15.3
US
Resmed Inc
NYSE:RMD
32B USD 16.1 21.5

Market Distribution

In line with most companies in the United States of America
Percentile
53rd
Based on 9 518 companies
53rd percentile
17.7
Low
0 — 11.7
Typical Range
11.7 — 23.6
High
23.6 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 11.7
Median 16.7
70th Percentile 23.6
Max 3 178 983.5

Becton Dickinson and Co
Glance View

Founded in 1897, Becton Dickinson and Co., commonly known as BD, embarked on its journey with the vision to improve medical discovery and diagnostics. Over the decades, BD has transformed from a small syringe and needle manufacturer to a global leader in the medical technology industry. Situated in Franklin Lakes, New Jersey, BD has carved out a prominent place through its steadfast commitment to addressing health care workers' requirements and enhancing patient outcomes. The company's diversified portfolio spans across three major segments: BD Medical, BD Life Sciences, and BD Interventional. This trinity of divisions underscores BD's prowess in producing a broad range of medical supplies, laboratory equipment, and diagnostic products that find their way into hospitals, research facilities, and clinics worldwide. The company operates primarily by innovating and supplying products that are indispensable to everyday medical care and scientific research. BD’s robust revenue stream is bolstered by its strategic approach to integrating new technologies and acquiring innovative smaller companies that complement its core offerings. Through strategies like these, BD continuously adapts to the evolving healthcare landscape. Its products, such as advanced syringes, safety-engineered devices, and sophisticated laboratory equipment, are deeply embedded in the healthcare system, making BD a critical part of the global push for improved health outcomes. The company’s blend of consistent product demand and strategic innovations secures a stable financial footing, allowing it to invest further in research and development while extending its market reach across the globe.

BDX Intrinsic Value
228.74 USD
Undervaluation 32%
Intrinsic Value
Price $154.85
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett